Dendritic_JJ
cells_NNS
and_CC
the_DT
pathogenesis_NN
of_IN
rheumatoid_JJ
arthritis_NN
._.

Rheumatoid_JJ
arthritis_NN
-LRB-_-LRB-
RA_NN
-RRB-_-RRB-
is_VBZ
a_DT
chronic_JJ
autoimmune_JJ
inflammatory_JJ
disease_NN
in_IN
which_WDT
unknown_JJ
arthrogenic_JJ
autoantigen_NN
is_VBZ
presented_VBN
to_TO
CD4_NN
+_CC
T_NN
cells_NNS
._.

The_DT
strong_JJ
association_NN
of_IN
the_DT
disease_NN
with_IN
an_DT
epitope_NN
within_IN
the_DT
HLA-DR_NN
chain_NN
shared_VBN
between_IN
various_JJ
alleles_NNS
of_IN
HLA-DR4_NN
and_CC
DR1_NN
emphasizes_VBZ
the_DT
importance_NN
of_IN
antigen_NN
presentation_NN
._.

This_DT
immune_JJ
response_NN
predominantly_RB
occurs_VBZ
in_IN
the_DT
synovial_JJ
tissue_NN
and_CC
fluid_NN
of_IN
the_DT
joints_NNS
and_CC
autoreactive_JJ
T_NN
cells_NNS
are_VBP
readily_RB
demonstrable_JJ
in_IN
both_CC
the_DT
synovial_JJ
compartment_NN
and_CC
blood_NN
._.

Circulating_VBG
dendritic_JJ
cells_NNS
-LRB-_-LRB-
DC_NN
-RRB-_-RRB-
are_VBP
phenotypically_RB
and_CC
functionally_RB
identical_JJ
with_IN
normal_JJ
peripheral_JJ
blood_NN
-LRB-_-LRB-
PB_NN
-RRB-_-RRB-
DC_NNS
._.

In_IN
the_DT
synovial_JJ
tissue_NN
,_,
fully_RB
differentiated_VBN
perivascular_JJ
DC_NNS
are_VBP
found_VBN
in_IN
close_JJ
association_NN
with_IN
T_NN
cells_NNS
and_CC
with_IN
B_NN
cell_NN
follicles_NNS
,_,
sometimes_RB
containing_VBG
follicular_JJ
DC_NNS
._.

These_DT
perivascular_JJ
DC_NN
migrate_VBP
across_IN
the_DT
activated_VBN
endothelium_NN
from_IN
blood_NN
and_CC
receive_VBP
differentiative_JJ
signals_NNS
within_IN
the_DT
joint_NN
from_IN
monocyte-derived_JJ
cytokines_NNS
and_CC
CD40-ligand_NN
+_CC
T_NN
cells_NNS
._.

In_IN
the_DT
SF_NN
,_,
DC_NN
manifest_VBP
an_DT
intermediate_JJ
phenotype_NN
,_,
similar_JJ
to_TO
that_DT
of_IN
monocyte-derived_JJ
DC_NNS
in_FW
vitro_FW
._.

Like_IN
a_DT
delayed-type_JJ
hypersensitivity_NN
response_NN
,_,
the_DT
rheumatoid_JJ
synovium_NN
represents_VBZ
an_DT
effector_NN
site_NN
._.

DC_NN
at_IN
many_JJ
effector_NN
sites_NNS
have_VBP
a_DT
characteristic_JJ
pattern_NN
of_IN
infiltration_NN
and_CC
differentiation_NN
._.

It_PRP
is_VBZ
important_JJ
to_TO
note_VB
that_IN
the_DT
effector_NN
response_NN
is_VBZ
not_RB
self-limiting_JJ
in_IN
RA_NN
autoimmune_JJ
inflammation_NN
._.

In_IN
this_DT
article_NN
,_,
we_PRP
argue_VBP
that_IN
the_DT
presentation_NN
of_IN
self-antigen_NN
by_IN
DC_NN
and_CC
by_IN
autoantibody-producing_JJ
B_NN
cells_NNS
is_VBZ
critical_JJ
for_IN
the_DT
perpetuation_NN
of_IN
the_DT
autoimmune_JJ
response_NN
._.

Permanently_RB
arresting_VBG
this_DT
ongoing_JJ
immune_JJ
response_NN
with_IN
either_CC
pharmaceutical_JJ
agents_NNS
or_CC
immunotherapy_NN
is_VBZ
a_DT
major_JJ
challenge_NN
for_IN
immunology_NN
._.

